Clinical trials
Neoplasms clinical trials
Below are recruiting neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,642 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05242861Recruiting
Reviewing outcomes after brachytherapy for women’s cancers
This study looks back at medical records to understand results after brachytherapy (a form of cancer radiation delivered from inside or close to the tumor) in women with gynecologic cancer. It may help doctors improve future treatment decisions, but you would not have to receive an experimental treatment.
Hangzhou, ZhejiangAges 18–80 - NCT06118723Recruiting
Supramaximal vs maximal surgery for brain tumors
This trial compares removing as much tumor as safely possible (supramaximal resection) with standard maximal resection in people with high-grade glioma (an aggressive brain tumor). The goal is to see if more extensive removal improves survival and quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06630962Recruiting
Financial help for newly diagnosed cancer patients
This study looks at whether getting help with financial issues (like insurance and costs) can reduce the money worries and problems that come with cancer treatment. It is for people newly diagnosed with breast, colorectal, or prostate cancer who haven't started treatment yet.
Ile-IfeAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT06033976Recruiting
Registry for endoscopic removal of digestive tract growths
This study collects information on people who are having a procedure called endoscopic submucosal dissection to remove abnormal growths in the digestive tract. It helps doctors learn more about how well the procedure works and who benefits most.
BucharestAges 18–100 - NCT07612280RecruitingPhase 1/Phase 2
Testing JBI-802 for blood cell disorders with high platelets
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Sydney, New South WalesAges 18 years+ - NCT07424664RecruitingPhase 2
Combination targeted drug and immunotherapy for recurrent gynecologic cancers
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Wuhan, HubeiAges 18–75 - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07065604Recruiting
Tubeless surgery for chest tumor
This trial tests a new way to remove a chest tumor without using a breathing tube or chest tube. If you have a small mediastinal tumor and are in good health, you might be able to have a less invasive surgery.
Guangzhou, GuangdongAges 18–80 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06676527Recruiting
Vorolanib for advanced kidney cancer after first treatment
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Nanjing, JiangsuAges 18–80 - NCT06680089RecruitingPhase 2
Imaging test for kidney cancer using CD70-targeted drug
This trial uses a special imaging drug that targets CD70 (a protein on some kidney cancer cells) to see if it can better detect and track kidney tumors. It may help doctors understand how much cancer is present and guide treatment decisions.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT06251544RecruitingPhase 1
CAR T cells for HER2-positive metastatic breast cancer
This trial tests a new type of immune cell therapy (CAR T cells) that targets two markers on cancer cells: TRAIL-R2 and HER2. It is for people with advanced or recurrent HER2-positive breast cancer that has not been stopped by standard treatment.
Houston, TexasAges 18–80 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Birmingham, AlabamaAges 18 years+ - NCT06023862RecruitingPhase 2
Study of dostarlimab and bevacizumab for recurrent clear cell cancer
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
Clayton, Clayton Rd.Ages 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05868226RecruitingPhase 1/Phase 2
Personalized cancer treatment study for advanced solid tumors
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Birmingham, AlabamaAges 18 years+ - NCT05549661RecruitingPhase 1
Onvansertib for hard-to-treat CMML and MDS/MPN
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Rochester, MinnesotaAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoplasms?
- Yes. Clin2 currently lists 1,642 recruiting neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.